

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019893 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2003/027523

(22) International Filing Date:
2 September 2003 (02.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/231,956 30 August 2002 (30.08.2002) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 10/231,956 (CIP)
Filed on 30 August 2002 (30.08.2002)

(71) Applicant (for all designated States except US): **RIGEL
PHARMACEUTICALS, INC.** [US/US]; 1180 Veterans
Blvd., South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LORENS, James, B.**

[US/NO]; Kraakenesveien 10, N-5152 Bones (NO). **BO-
GENBERGER, Jakob** [DE/US]; 3028 Central Avenue,
Ventura, CA 93003 (US). **HOLLAND, Sacha** [GB/US];
518 Foerster Street, Apt. B, San Francisco, CA 94127
(US). **XU, Weiduan** [CN/US]; 1800 22nd Avenue, Apt.
203, San Francisco, CA 94122 (US).

(74) Agents: **KELLY, Beth, L.** et al.; Townsend and Townsend
and Crew LLP, Two Embarcadero Center, 8th Floor, San
Francisco, CA 94111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]


(54) Title: MODULATORS OF ANGIOGENESIS

GFP-ΔN-Plakoglobin Expression in Endothelial Cells Downregulates αvβ3 Surface Levels


Functional Screening Hit

Plakoglobin

GFP-ΔN-Plakoglobin



FACS Analysis



(57) Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding "angiogenesis regulatory proteins and nucleic acids" which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.